Novo Nordisk: Lower outlook mainly linked to US market

July 29 (Reuters) - Novo Nordisk A/S NOVOb.CO:

• NOVO NORDISK BOARD CHAIR LUND: NEW CEO DOUSTDAR IS AN OUTSTANDING LEADER AND TRULY COMMITTED TO NOVO NORDISK, OUR PURPOSE AND THE PATIENTS WE SERVE

• NOVO NORDISK INCOMING CEO DOUSTDAR: IT'S REALLY A PRIVILEGE TO GET THIS JOB

• NOVO NORDISK INCOMING CEO DOUSTDAR: NOVO WILL ACT WITH URGENCY, SHARPEN OUR FOCUS, OPERATE MORE EFFICIENTLY

• NOVO NORDISK INCOMING CEO DOUSTDAR: WE NEED TO INCREASE THE SENSE OF URGENCY AND EXECUTE DIFFERENTLY

• NOVO NORDISK INCOMING CEO DOUSTDAR: THE FACT THAT MY ANNOUNCEMENT COMES RIGHT AFTER THE GUIDANCE UPDATE, IT JUST MAKES THE MANDATE AHEAD EVEN MORE CLEAR

• NOVO NORDISK CFO: UNLAWFUL COMPOUNDING OF SEMAGLUTIDE CONTINUES AND CALLS FOR AGGRESSIVE INTERVENTION BY U.S. LAW ENFORCEMENT

• NOVO NORDISK CFO: WEGOVY PENETRATION IN DIRECT TO CONSUMER CHANNEL IS BELOW EXPECTATIONS DUE TO ONGOING COMPOUNDING

• NOVO NORDISK CFO: WILL CONTINUE TO SCALE UP DIRECT TO CONSUMER SALES OF WEGOVY

• NOVO NORDISK CFO: SOME POSITIVE DEVELOPMENTS IN WEGOVY PRESCRIPTONS IN U.S.

• NOVO NORDISK CFO: OZEMPIC SALES NEGATIVELY AFFECTED BY COMPETITION IN THE U.S. MARKET

• NOVO NORDISK CFO: EXPECTS A POSITIVE VOLUME CONTRIBUTION FROM THE CHANGES TO THE CVS NATIONAL TEMPLATE FORMULARY

• NOVO NORDISK CFO: THE APPLIED SALES GROWTH IN H2'25 IS MID-SINGLE DIGITS

• NOVO NORDISK CFO: THE LOWERING OF OUTLOOK IS PREDOMINANTLY LINKED TO THE PERFORMANCE OF OUR U.S. BUSINESS

• NOVO NORDISK CFO: OUR LATEST MARKET RESEARCH STILL INDICATES 1 MILLION U.S. PATIENTS BEING ON COMPOUNDED OBESITY DRUGS

• NOVO NORDISK HEAD OF U.S. OPERATION MOORE: WE CONTINUE TO SEE SLOWER GROWTH OF GLP ON DIABETES; TO SOME DEGREE THERE'S ALSO AN IMPACT FROM COMPOUNDING

• NOVO NORDISK INCOMING CEO DOUSTDAR: WE WILL BE FASTER AND MORE DECISIVE IN OUR DECISION MAKING

• NOVO NORDISK HEAD OF U.S. OPERATION MOORE: WE BELIEVE THERE'S STILL SUBSTANTIAL GROWTH OPPORTUNITY IN THE U.S. FOR GLP-1S, THIS IS IN BOTH DIABETES AND IN OBESITY

• NOVO NORDISK CFO: THE MARKET SHOULD EXPECT THAT THE AVERAGE PRICING OF WEGOVY IN THE UNITED STATES TO GO DOWN

• NOVO NORDISK INCOMING CEO DOUSTDAR: IN A HANDFUL OF MARKETS OUTSIDE THE U.S. WE ARE RIGHT NOW NOT THE LEADING PLAYER

• NOVO NORDISK HEAD OF U.S. OPERATION MOORE: THERE'S STILL A TREMENDOUS OPPORTUNITY IN THE U.S. MARKET; WE NOW HAVE INSURANCE COVERAGE FOR OVER WITH OVER 55 MILLION PEOPLE

• NOVO NORDISK HEAD OF U.S. OPERATION MOORE: WE ARE SEEING WEGOVY AS OF LATE AROUND 275,000 PRESCRIPTIONS PER WEEK

Further company coverage: [NOVOb.CO]